Rigel Pharma (RIGL) Misses Q2 EPS by 4c

Rigel Pharma (NASDAQ: RIGL) reported Q2 EPS of ($0.06), $0.04 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $36.84 million versus the consensus estimate of $33.7 million.

For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.

You May Also Be Interested In

• Gulfport Energy and Mobility Global to join S&P SmallCap 600
• Tianci International updates Zimbabwe gold and chromium project progress
• Stardust Solar closes final tranche, raises $832,880 in total